Fluticasone-umeclidinium-vilanterol (Trelegy)
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Fluticasone-umeclidinium-vilanterol (Trelegy) (brand name Trelegy) — COPD and asthma controller; Inhaled corticosteroid plus LAMA plus LABA (triple therapy).
Identification
- Therapeutic class: COPD and asthma controller.
- Pharmacologic class: Inhaled corticosteroid plus LAMA plus LABA (triple therapy).
Pharmacology
- Mechanism of action: Combines anti-inflammatory, anticholinergic, and beta-agonist bronchodilation.
- Onset / peak / duration: 24-hour effect.
- Half-life / therapeutic level: No routine level.
Clinical use
- Indications: COPD and asthma maintenance.
- Usual dose, route, frequency: Inhaled once daily.
- Maximum dose / adjustments: Once daily only.
Safety
- Contraindications: Acute bronchospasm primary treatment.
- Black box warning: None.
- Interactions: CYP3A4 inhibitors, beta blockers, other anticholinergics, QT-prolonging drugs.
- Pregnancy / lactation: Use if needed.
- High-alert: No.
Adverse effects
- Common side effects: Thrush, dry mouth, headache, upper respiratory symptoms.
- Serious effects to report: Paradoxical bronchospasm, glaucoma, urinary retention.
- Antidote / reversal: Supportive care.
Nursing process
- Assessment before administration: Respiratory status, glaucoma and prostate history, oral mucosa.
- Interventions during therapy: Once daily; rinse mouth; keep a rescue inhaler.
- Monitor: Symptom control.
- Evaluation / expected outcome: Improved control.
Patient teaching
- Patient teaching: Once-daily controller; rinse after; not a rescue.
- Notify provider if: Eye or urinary symptoms, worsening breathing.
- Administration tips: Same time daily; rinse mouth.